Yadav, Pragya ; Mohandas, Sreelekshmy ; Sarkale, Prasad ; Nyayanit, Dimpal ; Shete, Anita ; Sahay, Rima ; Potdar, Varsha ; Baradkar, Shrikant ; Gupta, Nivedita ; Sapkal, Gajanan ; Abraham, Priya ; Panda, Samiran ; Bhargava, Balram (2022) Isolation of SARS-CoV-2 B.1.1.28.2 (P2) variant and pathogenicity comparison with D614G variant in hamster model Journal of Infection and Public Health, 15 (2). pp. 164-171. ISSN 1876-0341
Full text not available from this repository.
Official URL: http://doi.org/10.1016/j.jiph.2021.12.009
Related URL: http://dx.doi.org/10.1016/j.jiph.2021.12.009
Abstract
Background Considering the potential threat from emerging Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2) variants and the rising COVID-19 cases, SARS-CoV-2 genomic surveillance is ongoing in India. We report herewith the isolation of the P.2 variant (B.1.1.28.2) from international travelers and further its pathogenicity evaluation and comparison with D614G variant (B.1) in hamster model. Methods Virus isolation was performed in Vero CCL81 cells and genomic characterization by next generation sequencing. The pathogenicity and host immune response of the isolate was assessed in Syrian hamster model and compared with B.1 variant. Results B.1.1.28.2 variant was isolated from nasal/throat swabs of international travelers returned to India from United Kingdom and Brazil. The B.1.1.28.2 variant induced body weight loss, viral replication in the respiratory tract and caused severe lung pathology in infected Syrian hamster model in comparison, with B.1 variant infected hamsters. The sera from B.1.1.28.2 infected hamsters efficiently neutralized the D614G variant virus whereas 6-fold reduction in the neutralization was seen in case of D614G variant infected hamsters’ sera with the B.1.1.28.2 variant. Conclusions B.1.1.28.2 lineage variant could be successfully isolated and characterization could be performed. Pathogenicity of the isolate was demonstrated in Syrian hamster model and the findings of neutralization reduction is of great concern and point towards the need for screening the vaccines for efficacy.
Item Type: | Article |
---|---|
Source: | Copyright of this article belongs to Elsevier B.V.. |
ID Code: | 125469 |
Deposited On: | 07 Feb 2022 10:23 |
Last Modified: | 07 Feb 2022 10:23 |
Repository Staff Only: item control page